NAD IV Therapy: What the Research Actually Shows

You've probably seen the claims. Clinics promising NAD IV therapy will fix your fatigue, sharpen your brain, reverse your age, and cure your addiction. Celebrities talk about it. Longevity podcasters debate it. Wellness clinics across the country are charging $400–$800 a session for it.

So what does the science actually say?

The honest answer is: NAD IV therapy has real biological rationale, promising early data in specific conditions, and a lot of unanswered questions. It is not FDA-approved as a standalone medical treatment. The clinical trial evidence is preliminary. And yet, for certain people (those with chronic fatigue, mitochondrial conditions, or going through addiction recovery) there are real physicians seeing real results in clinical practice.

This guide walks through what NAD+ actually does in your body, why the IV route matters, what to expect during an infusion (including the chest tightness everyone asks about), and the honest comparison between IV therapy and oral supplements like NMN and NR. By the end, you'll have enough information to decide whether it's worth exploring with a physician.

What NAD+ Actually Does in Your Body

Your body runs on NAD+. It is present in every cell (except red blood cells, which operate on a purely glycolytic pathway and don't need it the same way). Without it, your mitochondria cannot produce energy, your sirtuins cannot regulate gene expression, and your DNA repair systems cannot function.

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme that sits at the center of three core processes your cells depend on:

Mitochondrial energy production. Your cells make ATP through the electron transport chain, and NAD+ is the primary electron carrier in that process. It accepts electrons during glycolysis and the citric acid cycle, then delivers them to the mitochondrial membrane to drive ATP synthesis. When NAD+ levels drop, ATP production drops with it. This is one reason low NAD+ correlates so consistently with fatigue.

Sirtuin activation. Sirtuins are proteins that regulate stress response, inflammation, and aging pathways. They require NAD+ as a cofactor and actually consume it in the process. As Peter Attia, MD and longevity researcher Matt Kaeberlein discussed on Attia's podcast ("NAD and NAD precursors: help or hype?"), sirtuins are NAD-dependent in a fundamentally different way than most metabolic reactions. They use NAD+ up rather than just cycling it (Kaeberlein & Attia, 2021). This means chronically low NAD+ translates directly to dampened sirtuin activity.

DNA repair. PARP enzymes (the proteins your cells deploy to fix DNA strand breaks) also require NAD+ as a substrate. They're particularly relevant here because NAD+ depletion and DNA damage are tightly coupled. A study in skin samples ranging from newborn to 77-year-old adults found that NAD+ levels declined with age in the same pattern as accumulated DNA damage (Marks & Xu, 2009).

Here is the problem: NAD+ levels decline significantly as we age. Studies in humans and animal models consistently show that by middle age, cellular NAD+ is roughly half what it was in youth. The question researchers have been wrestling with for the past decade is whether replacing it matters, and if so, how to do it effectively.

Why NAD IV Therapy Bypasses What Oral Supplements Can't

NAD+ is not easily absorbed through the gut when taken orally. The molecule itself is too large and polar to cross intestinal cell membranes efficiently. When you take an "NAD supplement" directly, most of it is broken down in your digestive system before it can reach the bloodstream.

This is the core argument for the IV route. NAD IV therapy delivers nicotinamide adenine dinucleotide directly into your bloodstream, bypassing first-pass metabolism entirely.

The pharmacokinetic reality is straightforward: a 500 mg IV infusion of NAD+ delivers 100% of that dose systemically. An oral dose of the same amount would deliver a fraction of that, depending on conversion efficiency and individual metabolism.

The 2024 pilot RCT from Hawkins et al. compared NAD+ IV (500 mg) directly against IV-administered nicotinamide riboside (NR at 500 mg) and oral NR (500 mg) in healthy adults (Hawkins et al., 2024). Key finding: NAD+ IV raised blood NAD+ levels faster and to higher peaks than any oral route. The tradeoff? It also caused more adverse experiences during infusion (nausea, chest tightness, and flushing) compared to IV NR and especially compared to the oral arm.

That flushing response is worth its own section.

The Chest Tightness During Infusion: What It Is and Why It Happens

Ask anyone who has had an NAD IV infusion what surprised them most, and chest tightness is almost always the first thing they mention.

David Sinclair, PhD (the Harvard genetics professor and NAD+ researcher who has tried the infusion himself) described it this way: "Like most people I experienced tightness in my tummy around my intestines... it wasn't too bad, wasn't anything that I was worried about, and then it subsided pretty quickly afterwards within just minutes" (Sinclair, via Reverse Aging Revolution, 2022).

Here is what is happening physiologically. NAD+ at high concentrations in the bloodstream causes peripheral vasodilation, with blood vessels widening rapidly in response to the body's response to the sudden systemic increase. This vasodilation, combined with the effect on smooth muscle in the chest and abdomen, is what most patients experience as pressure, tightness, or a flushing sensation. It typically spreads from the chest into the arms and face.

This is rate-dependent, not dose-dependent. Slower infusion rates reduce or eliminate the sensation entirely.

In practice, experienced clinicians manage this by slowing the drip rate when a patient starts to feel discomfort. The symptom resolves within minutes. It is not dangerous. It is not a sign of cardiac distress. It is a predictable pharmacological response to the rapid rise in NAD+ levels.

Dr. Payam Hakimi, MD, an anti-aging physician who has administered NAD IV therapy to many patients in his practice, is direct about this: the sensation is real, it is expected, and it is managed by adjusting infusion rate, not by stopping the infusion (Hakimi, 2020).

If a clinic is giving you a 500 mg infusion in 30 minutes, that is too fast. Typical infusion times run 2–4 hours for a 500–1000 mg dose. The Hawkins et al. 2024 RCT found that IV NR had a mean tolerable infusion time 75% shorter than NAD+ IV, meaning patients tolerated the NR faster but the direct NAD+ required slower infusion for comfort.

What the Clinical Evidence Actually Shows

The honest assessment here: most evidence for NAD IV therapy is empirical: physician observations in clinical practice rather than controlled trials. The RCT data that exists is mostly for oral NAD+ precursors, not IV administration.

The best direct IV study so far. The Hawkins et al. 2024 randomized, placebo-controlled pilot trial (n=53 across two phases) is the closest we have to rigorous IV-specific data. It confirmed safety and tolerability of NAD+ IV at 500 mg. Blood NAD+ levels rose significantly in the IV group versus placebo, with no serious adverse events through 14-day follow-up (Hawkins et al., 2024). This is good news. It is also a pilot study: small, short duration, healthy adults only, with no long-term outcomes measured.

Oral NMN and NR have stronger trial data. The NOPARK trial (NCT03568968) enrolled 410 early-stage Parkinson's patients and studied oral nicotinamide riboside supplementation over 52 weeks. The NAD-brain study (NCT05698771) investigated blood and brain pharmacokinetics of oral NR and NMN in healthy adults. A completed Mayo Clinic Phase 2 trial (NCT04342975) tested oral NR (combined with pterostilbene as "Basis") versus placebo in patients undergoing complex aortic surgery. These are the kinds of controlled, well-powered studies that establish clinical efficacy. For IV administration specifically, we are still mostly extrapolating from the pharmacokinetics data and physician experience.

Where IV therapy shows the most clinical promise. Physician experience and early data point to several populations where IV delivery may offer advantages over oral approaches:

Addiction recovery. The most established clinical use of NAD IV therapy is in substance abuse treatment, particularly alcohol and opioid addiction. Clinics have used high-dose NAD+ infusions (often 1,000–2,000 mg over several days) as part of medically supervised detox protocols. The proposed mechanism involves restoring NAD+-dependent signaling pathways that addiction depletes. The evidence base here is largely observational, but it's more developed than most other IV NAD+ applications.

Chronic fatigue and mitochondrial conditions. Patients with ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome) and mitochondrial disease show consistent cellular energy deficits. The argument for IV therapy in these patients is that bypassing gut absorption may deliver more NAD+ to depleted tissues. Physician experience in these populations has been positive, though controlled trial data is limited.

Neurodegenerative conditions. The NOPARK trial results for NR in Parkinson's disease were encouraging for the broader concept of NAD+ replenishment in neurodegeneration. Whether IV delivery adds benefit over oral approaches in this context is unknown.

NAD IV Therapy vs. Oral NMN and NR: The Honest Comparison

This is the question most people actually want answered: is the IV worth the premium over oral supplements?

The straightforward answer is: for most healthy people optimizing longevity, probably not. For specific conditions where absorption matters or blood levels need to rise rapidly, it is worth discussing with a physician.

Here is the framework:

Oral NMN and NR raise blood NAD+ meaningfully. A completed trial (NCT05517122, n=68) directly comparing NAM, NR, and NMN versus placebo in healthy adults confirmed that all three oral precursors raise whole blood NAD+ levels significantly. NMN at 600 mg in a multicenter double-blind RCT showed a 470% increase in NAD+ along with improvements in exercise capacity and biological markers (reported via r/Supplements based on SSRN preprint). These are real, measurable effects from oral supplementation.

IV delivers more, faster. But how much of that reaches intracellular compartments is unclear. Blood NAD+ levels rise more dramatically after IV infusion. Whether that translates to proportionally greater intracellular effect is the key unanswered question. Your cells don't just absorb circulating NAD+ directly. They use precursors and biosynthetic pathways. The Huberman and Attia discussion from July 2024 explored this point directly: Attia acknowledged that we know oral precursors raise blood NAD+, but the degree to which they raise intracellular NAD+, particularly in mitochondria, is not well established for either route (Huberman & Attia, 2024).

Sinclair's visual comparison. David Sinclair has framed this practically: with IV infusion, NAD+ levels spike high and then fall back down within days unless you're getting infusions frequently. With oral NMN taken daily, levels rise more slowly but reach a sustained baseline that "wobbles" throughout the day rather than spiking and crashing (Sinclair, 2022). For longevity purposes, sustained baseline elevation may be more valuable than episodic spikes.

The cost comparison matters. A single NAD IV session costs $300–$800. A month of oral NMN at 500–1,000 mg/day costs $30–$100 depending on brand. If you need weekly IV sessions to maintain elevated levels, you are looking at $1,200–$3,200/month versus $360–$1,200/year for oral supplementation.

The exception: situations where oral bioavailability is compromised (severe gut inflammation, malabsorption conditions, or acute need for rapid NAD+ elevation) and IV delivery's pharmacokinetic advantage becomes clinically meaningful.

Peter Attia's "Help or Hype" Perspective and the Cancer Question

Peter Attia is probably the most respected voice in longevity medicine who publicly engages with the NAD+ debate with genuine scientific rigor. His position is nuanced, and it is worth understanding.

Attia does not dismiss the NAD+ pathway. He finds the biology compelling. Sirtuins, PARP, the aging-related decline in cellular NAD+: all of it makes mechanistic sense. What he is cautious about is getting ahead of the evidence.

The specific concern Attia and Inigo San-Millan raised in a 2022 podcast exchange ("Potential Risks of NAD Supplements") is this: NAD+ depletion also appears to be a natural cellular defense against aberrant cell proliferation. Rapidly dividing cancer cells are hungry for NAD+. If chronically elevating systemic NAD+ levels helps cancer cells survive and proliferate along with healthy cells, that is a problem (Attia & San-Millan, 2022).

This is not a settled question. It is also not a reason to panic if you are a healthy person taking NMN or getting an occasional NAD IV infusion. The concern is theoretical, extrapolated from cancer cell biology, and has not been demonstrated in human outcomes data. But it is a legitimate reason to involve a physician who can review your cancer risk factors and personal medical history, before committing to chronic high-dose NAD+ supplementation.

The sirtuin story is similarly complicated. The original hypothesis from the late 1990s work in yeast was that sirtuins were the primary mediators of caloric restriction-based longevity. Later work by Matt Kaeberlein and Brian Kennedy showed that story was more nuanced across different yeast strains, and whether sirtuin activation translates to meaningful longevity benefits in humans remains an open question (Kaeberlein & Attia, 2021).

None of this means NAD+ therapy is dangerous or useless. It means the appropriate posture is "promising and plausible, being studied, requires physician oversight," not "anti-aging miracle."

Dosing: What Clinics Actually Use

Most NAD IV therapy protocols in clinical practice follow these general parameters:

Dose range: 250–1,000 mg per infusion. Typical starting doses are 250–500 mg, with experienced patients or those in addiction recovery protocols sometimes receiving higher doses.

Infusion time: 2–4 hours for 500–1,000 mg doses. Faster infusion correlates with stronger adverse effects (chest tightness, flushing, nausea). Slower is safer and more comfortable.

Loading phase: For new patients or therapeutic protocols (particularly addiction recovery), some clinicians run daily infusions for 3–10 consecutive days to rapidly saturate NAD+ levels.

Maintenance: After loading, most patients switch to monthly or quarterly infusions. Some high-frequency users do biweekly sessions during periods of high physiological stress.

Supplements between sessions. Most protocols combine IV therapy with daily oral NMN or NR to maintain elevated baseline levels between infusions. Dr. Hakimi recommends this approach, treating IV infusions as periodic "superchargers" rather than standalone treatment (Hakimi, 2020).

There is no FDA-approved dosing protocol for NAD IV therapy because the FDA has not approved NAD+ as a standalone intravenous treatment. These protocols are based on physician experience and the clinical pharmacology literature. Compounding pharmacies prepare the NAD+ solutions for infusion under individual prescriptions.

FDA Status, WADA, and What "Not Approved" Actually Means

FDA status. NAD+ is not FDA-approved as a standalone intravenous medical treatment. What exists FDA-registered is a transdermal NAD+ patch (listed in openFDA drug label data as an OTC product). IV NAD+ therapy is offered through wellness clinics and functional medicine practices as an off-label compound, prepared by compounding pharmacies under state pharmacy law. This is legal. It is the same framework used for many physician-prescribed compounds that are not on the standard FDA approval track.

This means patients should ask their clinic: who compounds your NAD+, and what is their pharmacy's accreditation? PCAB-accredited or state-board-inspected compounding pharmacies are a meaningful quality signal.

WADA status. NAD+ is not on the World Anti-Doping Agency prohibited list. Athletes can use NAD IV therapy without needing a Therapeutic Use Exemption (TUE). This is confirmed by the current WADA prohibited list, which does not include NAD+ or its precursors in any prohibited substance category.

FAERS context. The FDA Adverse Event Reporting System (FAERS) database shows approximately 842,665 adverse event reports filed for substances in the NAD/niacin category broadly. The serious events in this database are: 100 serious reports. The top reactions were pain, dyspnoea, and abdominal pain, with single-digit counts each. This is a remarkably clean safety signal for a compound with this volume of clinical use. For context, the FAERS database includes reports for niacin, nicotinamide, and related compounds that vastly outnumber NAD+ IV-specific events. The adverse event rate for NAD IV therapy specifically is low.

Cost, Coverage, and How to Access NAD IV Therapy

Cost per session. Expect $300–$800 per infusion at most wellness clinics and functional medicine practices in the US. High-end concierge clinics in major metro areas charge toward the top of that range. Mobile IV therapy services (in-home infusions) typically run $200–$500.

Insurance coverage. NAD IV therapy is not covered by insurance for wellness or anti-aging indications. In some cases, infusions ordered by a physician for a specific medical diagnosis (addiction recovery under medical supervision, for example) may have partial billing pathways, but do not expect coverage. This is an out-of-pocket expense.

Session frequency and total cost. A loading protocol of 5–10 daily infusions runs $1,500–$8,000 upfront. Monthly maintenance infusions at $400/session run $4,800/year. That is the realistic cost commitment for someone using this therapeutically.

Comparing to oral alternatives. Quality NMN at 500–1,000 mg/day costs roughly $60–$100/month from reputable brands. That is the full-year cost of a single mid-range IV session. For people interested in chronic NAD+ support, oral supplementation is the rational starting point, and many physicians recommend it as the maintenance layer between IV sessions regardless.

How to access it through HEXIS. At HEXIS Health, NAD IV therapy protocols start with a physician consultation. Your provider will review your health history, current medications, cancer risk factors, and goals before recommending IV therapy versus oral supplementation versus a combination protocol. We do not prescribe IV NAD+ on a consultation alone. Your full picture matters.

Schedule a consultation to discuss whether NAD IV therapy is appropriate for your situation.

Who Actually Benefits Most from NAD IV Therapy

Based on clinical experience and the available evidence, these are the populations where IV delivery appears to offer meaningful advantages over oral supplementation alone:

Active addiction recovery. The most established use case. High-dose IV NAD+ has been used in medically supervised detox to reduce withdrawal intensity, restore neurochemical balance, and support the transition out of dependence. Patients going through alcohol or opioid detox under physician supervision are the strongest evidence-based candidates.

Chronic fatigue and mitochondrial dysfunction. Patients with ME/CFS, long COVID-associated fatigue, or confirmed mitochondrial conditions who have not responded adequately to oral NMN or NR. In these patients, compromised gut function or metabolic efficiency may limit oral absorption enough that IV delivery provides a meaningful pharmacokinetic advantage.

Post-surgery or high-recovery demand periods. The Mayo Clinic trial (NCT04342975) investigated NR in patients undergoing complex aortic surgery, suggesting NAD+ replenishment may support tissue recovery under high-stress conditions. The IV route for acute post-surgical recovery is an area of active clinical interest.

Patients with confirmed low NAD+ on blood testing. If you have actual lab data showing depleted NAD+ levels (some specialty labs offer whole blood NAD+ metabolome panels), that changes the calculus. Documented deficiency in a symptomatic patient is a different conversation than general optimization for a healthy person.

Who is probably not the ideal IV candidate: a generally healthy person in their 30s–40s seeking longevity optimization. For this group, daily oral NMN or NR at 500–1,000 mg represents a more rational, evidence-supported, and dramatically more affordable approach. See our NMN supplement physician review for the comparative data on oral precursors.

NAD+ and Longevity: What We Know vs. What We Don't

The longevity hypothesis around NAD+ is compelling because it connects three things that research has established independently: NAD+ declines with age, cellular aging correlates with depleted NAD+, and restoring NAD+ levels in aged animals improves multiple markers of health and lifespan.

Dr. Brad Stanfield, MD, who reviews longevity research systematically on his YouTube channel, traced the intellectual history clearly: the original discovery in Leonard Guarente's MIT lab showed that activating Sir2 (the yeast sirtuin) extended yeast lifespan, and NAD+ was the required cofactor. This led directly to the hypothesis that restoring NAD+ in aging mammals could replicate similar effects (Stanfield, 2025).

But translating yeast longevity data to human health outcomes is not straightforward. The sirtuin story in mammals is more complicated than the original yeast experiments suggested. And the human clinical trials that exist (measuring outcomes like disease progression, mortality, and functional aging) have not been completed yet at the scale needed to confirm the hypothesis.

What we have: strong mechanistic rationale, consistent evidence that oral precursors raise blood NAD+, preliminary evidence that this correlates with health markers in specific patient populations, and physician observations of patient benefit.

What we do not have: long-term randomized controlled trials showing that NAD+ IV therapy (or oral supplementation) extends human lifespan or prevents specific diseases at a population level.

Being honest about this gap matters. It does not mean the therapy is ineffective. It means the appropriate posture is cautious optimism with physician oversight, not the breathless marketing you see on clinic websites.

If you want to understand how NAD+ fits into a broader longevity supplement stack, our article on B12 injections covers another injectable protocol with stronger evidence for specific indications. For context on how injectable and peptide therapies are delivered in a physician-supervised setting, see our overview of what peptides are and how they work.

---

Frequently Asked Questions

Does NAD IV therapy actually work?

NAD IV therapy raises blood NAD+ levels more rapidly and to higher peaks than oral supplementation, confirmed by the 2024 Hawkins et al. pilot RCT. Whether that translates to clinical outcomes (improved energy, slower aging, better recovery) is supported by physician observation and mechanistic data but not yet by large-scale controlled trials. The evidence is promising, not definitive.

What does NAD IV therapy feel like, and why does it cause chest tightness?

Most patients experience warmth, chest pressure, or tightness during the infusion, particularly if the drip rate is too fast. This happens because NAD+ causes rapid peripheral vasodilation. It is not dangerous. The sensation resolves within minutes and is managed by slowing the infusion rate. A 500 mg infusion should take 2–4 hours for comfortable administration.

How much does NAD IV therapy cost per session?

NAD IV therapy costs $300–$800 per infusion at most US wellness and functional medicine clinics. Mobile in-home services run $200–$500. Insurance does not cover it for wellness or anti-aging purposes. Loading protocols of 5–10 consecutive sessions can run $1,500–$8,000 upfront.

Is NAD IV therapy better than NMN or NR oral supplements?

For most healthy people pursuing longevity optimization, oral NMN or NR is the rational first choice: it is dramatically less expensive ($60–$100/month vs. $300–$800/session), has more controlled trial data, and produces meaningful blood NAD+ elevation. IV therapy's advantage becomes most relevant when gut absorption is compromised, rapid NAD+ elevation is clinically needed (addiction recovery), or a physician determines oral approaches are insufficient based on lab data.

What are the side effects of NAD IV therapy?

The most common adverse effects are rate-dependent: chest tightness, flushing, warmth, nausea, and lightheadedness, all of which resolve when the infusion rate is slowed. The 2024 Hawkins et al. RCT found no attributable serious adverse events through 14-day follow-up. Long-term safety data for chronic high-dose IV administration is not established. The theoretical cancer concern warrants physician evaluation in anyone with elevated cancer risk.

---